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 Abstract 
  Background:   As of 2010, the rivastigmine patch was licensed for the treatment of Alzheimer’s 
disease (AD) in 64 countries.   Methods:   This 24-week, multicenter, randomized, double-blind, 
placebo-controlled study evaluated the efficacy, safety and tolerability of the 5-cm  2   (9-mg 
loading dose; 4.6 mg/24 h delivery rate) and 10-cm  2   (18-mg loading dose; 9.5 mg/24 h delivery 
rate) rivastigmine patch in Japanese patients with AD.   Results:   In the primary analysis popula-
tion (intent-to-treat last observation carried forward) at week 24, delayed deterioration was 
seen with the 10-cm  2   patch versus placebo on the Japanese version of the Alzheimer’s Disease 
Assessment Scale-cognitive subscale (ADAS-J cog; p = 0.005) and the Japanese version of the 
Clinician’s Interview-Based Impression of Change plus Caregiver Input (CIBIC plus-J; p = 0.067). 
Participants receiving the rivastigmine patch showed numerically less decline versus placebo 
at week 24 on the CIBIC plus-J, although this did not reach statistical significance. Statistical sig-
nificance for the CIBIC plus-J was met following adjustment for body weight and baseline Mini-
Mental State Examination score as dynamic allocation factors (p = 0.042) and on the Disability 
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Assessment for Dementia (DAD; p = 0.024) and Mental Function Impairment (MENFIS; p = 0.016) 
subscales. Serious adverse events were rare and were consistent with the known safety profile 
of the rivastigmine patch.   Conclusion:   The rivastigmine patch has a favorable efficacy and 
  tolerability profile in Japanese patients with AD.    Copyright © 2011 S. Karger AG, Basel 
 Introduction 
  There were an estimated 35.6 million people worldwide living with dementia in 2010, 
with numbers projected to nearly double every 20 years to 115.4 million persons in 2050   [1]  . 
There were 1.8 million patients living with dementia in Japan in 2005, with a total cost of 34 
billion USD   [2]  . Alzheimer’s disease (AD) is the main cause of dementia and one of the most 
burdensome conditions of later life   [3]  . A 2009 prospective study of the general Japanese 
population aged 65 years or over reported that Japanese elderly are at high risk of developing 
dementia, with an AD incidence of 14.6 cases per 1,000 person-years   [4]  .
    The primary treatment option for AD is the cholinesterase inhibitor drug class, which 
act by inhibiting cholinesterases, the enzymes responsible for degrading acetylcholine in the 
synaptic cleft   [5]  . Globally, rivastigmine, donepezil and galantamine are widely used to treat 
patients with mild-to-moderate AD   [5]  . As of the end of 2010, the rivastigmine transdermal 
formulation had been licensed for the treatment of patients with mild-to-moderate AD in 64 
countries worldwide, including those in the EU and the USA. However, at that time, done-
pezil was the only approved drug for the treatment of patients with AD in Japan. 
    Nausea and vomiting may be lessened by transdermal treatment due to reduced magni-
tude of peak plasma concentration (C  max ) and slower rate of rise in the plasma concentration 
(t  max  )   [6–8]  . In a multinational, double-blind, randomized, placebo-controlled study of riv-
astigmine patch versus capsule (IDEAL)   [8]  , statistically significant differences versus pla-
cebo were seen for the 10-cm  2   (18-mg loading dose; 9.5 mg/24 h delivery rate) rivastigmine 
patch and 12 mg/day capsule on the primary efficacy outcomes: AD Assessment Scale-cog-
nitive subscale (ADAS-cog)   [9]   and AD Cooperative Study-Clinical Global Impression of 
Change (ADCS-CGIC)   [8, 10]  . The 10-cm  2   rivastigmine patch demonstrated similar effi-
cacy to the highest dose of the rivastigmine capsule (12 mg/day) and a superior tolerability 
profile   [8] . 
    The pharmacokinetic and pharmacodynamic profile of rivastigmine patch has been 
shown to be similar in healthy Japanese and Caucasian individuals  [11] . However, drug expo-
sure was slightly higher and cholinesterase inhibition slightly more pronounced in Japanese 
participants than Caucasians. This was attributed to the lower body weight (approximately 
11% less on average) of Japanese participants. As a consequence, lower doses [e.g. the 5-cm  2  
rivastigmine patch (9-mg loading dose; 4.6 mg/24 h delivery rate)] may offer efficacy.
    The current study was designed to evaluate the efficacy, safety and tolerability of the 
5-cm  2   (9-mg loading dose; 4.6 mg/24 h delivery rate) and 10-cm  2   (18-mg loading dose; 9.5 
mg/24 h delivery rate) rivastigmine patch in Japanese patients with AD.
  M e t h o d s  
 Trial  Design 
  This was a 24-week, multicenter, randomized, double-blind, three-arm, placebo-con-
trolled, parallel-group, dose-finding study (ClinicalTrials.gov Identifier: NCT00423085). 
Following assessments for eligibility during a 4-week screening period, participants were 165
Dement Geriatr Cogn Disord Extra 2011;1:163–179
 DOI:  10.1159/000328929 
EXTRA
  Nakamura et al.: Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease 
www.karger.com/dee
  © 2011 S. Karger AG, Basel 
  Published online: June 24, 2011 
randomly assigned to one of three groups of equal size: the 5-cm  2   rivastigmine patch (9-mg 
loading dose; 4.6 mg/24 h delivery rate), the 10-cm  2   (18-mg loading dose; 9.5 mg/24 h deliv-
ery rate) rivastigmine patch or placebo.
  P a r t i c i p a n t s  
 The participants that met the inclusion criteria at randomization were 50- to 85-year-old 
male and female outpatients, not of child-bearing potential, had a diagnosis of dementia of 
the Alzheimer’s type according to the  Diagnostic and Statistical Manual of Mental Disorders , 
4th edition (DSM-IV) criteria, and probable AD according to the criteria of the National In-
stitute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Dis-
ease and Related Disorders Association (NINCDS/ADRDA)   [12]  . Participants required a 
Mini-Mental State Examination (MMSE)   [13]   score of   6  10 and   ^  20 and sufficient educa-
tion to read, write and communicate effectively during the premorbid state. They were re-
quired to be willing to cooperate and complete all aspects of the study and be capable of do-
ing so, either alone or with the aid of a responsible caregiver. The participant was required 
to be residing with a caregiver throughout the study or, if living alone, in contact with the 
primary caregiver every day. The caregiver was required to be the primary caregiver and to 
be willing to accept responsibility for supervising the treatment, assessing the condition of 
the patient throughout the study and for providing input to efficacy assessments according 
to protocol requirements. The caregiver had to directly assess the condition of the patient 
during the day and night of 4 days or more per week.
  Exclusion criteria at the time of randomization included any neurological or medical con-
dition other than AD that could explain the participant’s dementia, or an advanced, progres-
sive or unstable disease that could interfere with study assessments or put the participant at 
special risk (e.g. vascular dementia, major depression, severe cerebrovascular disease or severe 
cardiovascular disease). Other exclusion criteria included the use of rivastigmine in the past, 
or the use of donepezil, other cholinesterase inhibitors, approved treatments for AD or cen-
trally acting anticholinergic drugs during the 4 weeks prior to efficacy assessments at baseline.  
  Informed consent was obtained and the clinical study was designed, implemented and 
reported in accordance with applicable local regulations and with the ethical principles laid 
down in the Declaration of Helsinki.
  I n t e r v e n t i o n s  
  Participants were titrated to their target patch dose at 4-week intervals over 16 weeks, 
followed by an 8-week maintenance period through weeks 17–24 (  table 1  ). Four patch sizes 
were used in this study: 2.5-cm  2   (4.5-mg loading dose), 5-cm  2   (9-mg loading dose; 4.6 mg/
24 h delivery rate), 7.5-cm  2   (13.5-mg loading dose) and 10-cm  2   (18-mg loading dose; 9.5 mg/
24 h delivery rate). Participants in the rivastigmine treatment groups were titrated in 2.5-cm  2  
steps from a starting patch size of 2.5 cm  2   to their target patch size of 5 or 10 cm  2  . If the tar-
get dose was not reached during the titration period, the investigator could resume titration 
during the maintenance period. Dose adjustments and interruptions were permitted to allow 
the patient to continue on the study drug if any safety or tolerability aspects relating to the 
protocol-specified dosing schedule arose. The participants were maintained at their highest 
well-tolerated dose until the end of the study (week 24). The study drug was discontinued for 
a given patient if the investigator determined that continuing it would result in a significant 
safety risk for that patient.
  O u t c o m e s  
  Primary efficacy assessments were made at screening [Japanese version of ADAS-cog 
(ADAS-J cog) only], baseline (ADAS-J cog only), and weeks 8, 16 and 24. Primary efficacy 166
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assessments were the ADAS-J cog   [14]   and the Japanese version of the Clinician’s Interview-
Based Impression of Change plus Caregiver Input (CIBIC plus-J)   [15]  .
    Primarily used to evaluate cognitive function in AD patients, ADAS-cog is the most 
popular cognitive assessment instrument used in AD clinical trials all over the world. Test 
scores range from 0 (best) to 70 (worst), and when performed multiple times on an ongoing 
basis, the change in the overall score can be used to measure the change in cognitive func-
tion. 
    CIBIC plus-J is the Japanese version of the New York University School of Medicine 
CIBIC plus, a semi-structured interview format including a 7-point CGIC rating scale. It 
comprises three subscales: Disability Assessment for Dementia (DAD), Behavioral Pathology 
in AD (BEHAVE-AD) and Mental Function Impairment (MENFIS), discussed further as 
secondary assessments.
    Secondary efficacy assessments were baseline, week-8, -16 and -24 scores on the sub-
scales of the CIBIC plus-J (DAD, BEHAVE-AD and MENFIS) and screening, baseline and 
week-24 scores on the MMSE   [13]  .
    DAD is a 46-item structured interview or questionnaire for the caregiver that is scored 
from 0 to 100 (least impairment); it evaluates activities of daily living. BEHAVE-AD was de-
signed to assess potentially remediable behavioral symptoms in patients with AD as well as 
to evaluate treatment outcome. It consists of 22 symptoms grouped into 7 categories. Each 
symptom is scored by the caregiver on the basis of severity on a 4-point scale. MENFIS eval-
uates core symptoms of dementia including cognitive, motivational and emotional aspects 
based on interviews with the patient and information from the caregiver. Total scores range 
from 0 to 78; the higher the score, the greater the functional deficit.
    Exploratory assessments included evaluation for inhibition of plasma butyrylcholines-
terase (BuChE) activity, a questionnaire to evaluate caregiver experience of the rivastigmine 
patch compared with oral medication and scores on the Modified Crichton Scale from base-
line to week 24. The Modified Crichton Scale includes a total of 7 items evaluated in 8 grades 
that assess basic activities of daily living, communication functions, psychiatric symptoms 
and quality of life   [16]  .
    Safety evaluations included recording all adverse events on Adverse Event Case Report 
Forms. Every serious adverse event occurring after the patient provided informed consent 
and until 28 days after the patient stopped the study was reported. Medical examination and 
monitoring, assessment of vital signs, ECG, laboratory assessments and measurement of 
body weight were conducted at every visit. Skin irritation was assessed by the investigator 
and the investigator queried the caregiver about impression of skin irritation during patch 
Table 1. S  tudy design and interventions
Treatment 
group
Loading
dose
Delivery
rate
D  ouble-blind treatment phase
titration  maintenance
W1–4 W5–8 W9–12a W13–16b W17–24
Rivastigmine 
10 cm2  18 mg 9.5 mg/24 h 2.5 cm2 5 cm2 7.5 cm2 10 cm2 10 cm2
5 cm2  9 mg 4.6 mg/24 h 2.5 cm2 5 cm2 5 cm2 5 cm2 5 cm2
Placebo  control patients maintained on equivalent placebo patch size
a 5 -/2.5-  and  b 7.5-/2.5-cm2 patch size permitted for dose adjustment of decreased dose. W = Week.167
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application according to a caregiver’s rating scale. A rating of the patch adherence was pro-
vided and graded according to a patch adhesion score.
  S a m p l e   S i z e  
  The sample size calculation was based on change from baseline at week 24 on the two 
primary efficacy variables (ADAS-J cog and CIBIC plus-J). In order for the 5-cm  2   (9-mg 
loading dose; 4.6 mg/24 h delivery rate) or 10-cm  2  (18-mg loading dose; 9.5 mg/24 h delivery 
rate) patch to demonstrate efficacy versus placebo, superiority needed to be demonstrated on 
both efficacy variables. The assumptions on delta (difference in means) and standard devia-
tion (SD) for the change in ADAS-J cog and CIBIC plus-J were based on 24-week data from 
the IDEAL study   [8]  , which used the ADAS-cog   [9]   and ADCS-CGIC   [10]  . For the 10-cm  2  
rivastigmine patch to demonstrate superiority over placebo, estimated assumptions on delta 
(SD) were 3.1 (6.5) points for the ADAS-J cog and 0.37 (1.2) points for the CIBIC plus-J. For 
the 5-cm  2   patch, estimated assumptions were 2.1 (6.5) points on the ADAS-J cog and 0.37 
(1.2) points on the CIBIC plus-J. A hierarchical testing procedure was set up according to 
which the superiority of the 10-cm  2  rivastigmine patch versus placebo was to be shown first, 
followed by the superiority of the 5-cm  2   patch versus placebo. Each of the two hypotheses 
was to be tested simultaneously for ADAS-J cog and for CIBIC plus-J. The      level for each 
test was 5%. Due to the hierarchical procedure with simultaneous testing of ADAS-J cog and 
CIBIC plus-J, no    correction was required. In order to reach an overall power of at least 76% 
for the two hypotheses, based on the above assumptions, 232 participants were required per 
treatment group for a total of 696 patients. Assuming 10% of the patients would not be avail-
able for inclusion into the primary analysis population, 774 participants (258/arm) were in-
tended from randomization.
  R a n d o m i z a t i o n  
 On the day of randomization, the investigator confirmed that the first registered patient 
met all of the inclusion and exclusion criteria. The investigator ensured that all patients who 
met the inclusion and exclusion criteria were offered enrollment into the study. No addition-
al exclusions were permitted to be applied by the investigator to ensure that the study popu-
lation was representative of all eligible patients. Eligibility criteria were checked strictly on a 
rotating basis by a panel of 4 physicians. The Patient Registration Center provided a random-
ization number to the eligible participants and randomization lists were generated by a Study 
Drug Allocation Controller. A dynamic allocation was utilized for randomization. Only 2 
allocation factors were utilized: body weight ( ! 45, 45 to  ! 55,  6 55 kg) and MMSE score ( ^ 15  
or   1 15  points).
  B l i n d i n g  
  Patients, investigator staff, persons performing the assessments and data analysts were 
all blinded to the identity of the treatment from the time of randomization. Randomization 
data were kept strictly confidential by the Study Drug Allocation Controller until the time 
of unblinding and were not accessible by anyone else involved in the study. Pharmacokinet-
ic and pharmacodynamic data were not reported to the sponsor (except for analytical per-
sonnel) and investigator prior to unblinding. Unblinding was only permitted in the case of 
patient emergencies and at the conclusion of the study.
  Statistical  Methods 
  Study participants who had at least 1 dose of study medication and at least 1 safety eval-
uation post-baseline were considered for safety analysis (the ‘safety population’). The main 
efficacy analysis was based on the intent-to-treat (ITT) population using a last observation 168
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carried forward (LOCF) imputation. This ITT-LOCF population was pre-defined as all ran-
domized patients who received at least 1 dose of study medication and had at least 1 assess-
ment pre- and post-baseline for 1 of the primary efficacy variables on treatment (i.e. not more 
than 2 days after the last known date of study drug). Additional supportive analyses were 
included to confirm whether imputations and early discontinuations influenced the results. 
These included the ITT population without imputation (observed case, ITT-OC), all ITT 
patients who completed the trial without any major deviations from the protocol procedures 
(per protocol, PP) and all randomized patients who received at least 1 dose of study drug and 
had at least 1 assessment at baseline and any 1 post-baseline for 1 of the primary efficacy 
variables [modified ITT (MITT)].
    Statistical analyses were performed using SAS software (version 8.2). Changes from 
baseline to week 24 on the ADAS-J cog were assessed by analysis of covariance (ANCOVA), 
with baseline values as covariates and treatment groups as factors. Point estimates and 95% 
confidence intervals (CIs) for the treatment mean differences between each of the patch dos-
es versus placebo were reported. 
    Treatment comparisons on the CIBIC plus-J were performed using the Wilcoxon rank 
sum test. The proportional odds regression model was used to determine whether partici-
pants treated with rivastigmine were more likely to have a favorable response on week 24 
scores of the CIBIC plus-J. Supportive analyses were conducted on the dichotomized CIBIC 
plus-J variable (with levels ‘improvement’ and ‘no response’) using Fisher’s exact test. Analy-
ses for ADAS-J cog and CIBIC plus-J were carried out for the ITT-LOCF population and re-
peated for the ITT-OC, PP and MITT populations to assess the sensitivity of the results. No 
interim analyses were performed for this study.
    All analyses were pre-specified in the statistical analysis plan with the exception of
the secondary efficacy evaluations of CIBIC plus-J subscales (DAD, BEHAVE-AD and 
  MENFIS), which were post-hoc analyses. 
  R e s u l t s  
 Participants 
  The first participant was screened in January 2007 and the last participant completed 
the study in March 2009. Of 859 participants who were randomized, 284 were allocated to 
the 5-cm  2   (9-mg loading dose; 4.6 mg/24 h delivery rate) rivastigmine patch group, 287 to 
the 10-cm  2  (18-mg loading dose; 9.5 mg/24 h delivery rate) rivastigmine patch group and 288 
to the placebo group. Of the patients who were randomized, 856 (99.7%) received the study 
drug and 690 (80.3%) completed the study (  fig. 1  ). The safety population comprised 855 pa-
tients and the ITT-LOCF population comprised 810 patients.
    Demographics and background/disease characteristics are summarized in   table 2  . The 
mean (  8  SD) age of the safety population was 74.6 (  8  7.22) years and the majority of patients 
(68.3%) were female. The overall mean ( 8 SD) body weight at baseline was 50.7 ( 8 9.39; range 
31.0–87.1) kg. The mean ( 8 SD) MMSE total score at baseline for the overall study population 
was 16.6 (  8  2.96) points. The majority (68.7%) had a baseline MMSE total score    1 15.  The 
baseline demographics and background/disease characteristics were similar across all treat-
ment groups (  table 2  ).
  D o s i n g  
  In the 5-cm  2   (9-mg loading dose; 4.6 mg/24 h delivery rate) and 10-cm  2   (18-mg loading 
dose; 9.5 mg/24 h delivery rate) rivastigmine patch groups, 91.5 and 83.7% of participants, 
respectively, reached their target dose at the end of the maintenance period in week 24.169
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  E f f i c a c y  
  Primary Efficacy Assessments 
  ADAS-J Cog.   Participants receiving the rivastigmine patch showed less decline than 
those receiving placebo at week 24 on the ADAS-J cog (ITT-LOCF primary analysis popula-
tion;   fig. 2  ;   table 3  ). Least-square (LS) means  of the changes versus placebo were –0.8 points 
(95% CI, –1.7 to 0.0 points; p = 0.063) for the 5-cm  2  (9-mg loading dose; 4.6 mg/24 h delivery 
rate) rivastigmine patch and –1.2 points (95% CI, –2.1 to –0.4 points; p = 0.005) for the
10-cm  2   (18-mg loading dose; 9.5 mg/24 h delivery rate) rivastigmine patch.    Results  were 
similar with the supporting MITT, ITT-OC and PP populations (  table 3  ). The significant 
delayed progression of worsening in week 24 ADAS-J cog scores with the 10-cm  2   rivastig-
mine patch remained when the ANCOVA model was adjusted for the dynamic allocation 
factors of body weight and MMSE (p = 0.004).    
   CIBIC Plus-J.   Participants in the rivastigmine patch group tended to show less decline 
than those in the placebo group at week 24 on the CIBIC plus-J, although this did not reach 
statistical significance in the primary analysis ITT-LOCF population (  table 4  ). Results were 
similar with the supporting MITT, ITT-OC and PP populations, though in the PP popula-
tion the 10-cm  2   (18-mg loading dose; 9.5 mg/24 h delivery rate) rivastigmine patch group 
reached statistical significance versus the placebo group (p = 0.029;   table 4  ). Proportional 
odds regression demonstrated that participants treated with rivastigmine were more likely 
to have a favorable response on week-24 scores of the CIBIC plus-J, with odds ratios (ORs) of 
Placebo (n = 288)
  Received allocated intervention (n = 286)
  Discontinued: protocol deviation (n = 1)
  Discontinued: lost to follow-up (n = 1)
Rivastigmine 5 cm2 patch (n = 284)
  Received allocated intervention (n = 283)
  Discontinued: protocol deviation (n = 1)
Rivastigmine 10 cm2 patch (n = 287)
  Received allocated intervention (n = 287)
16.0% discontinued (n = 46)
  7.3% adverse events (n = 21)
  2.8% withdrew consent (n = 8)
  2.4% unsatisfactory therapeutic effect (n = 7)
  2.8% protocol deviation (n = 8)
  0.3% death (n = 1)
  0.3% lost to follow-up (n = 1)
22.5% discontinued (n = 64)
  13.4% adverse events (n = 38)
  5.6% withdrew consent (n = 16)
  2.1% unsatisfactory therapeutic effect (n = 6)
  1.1% protocol deviation (n = 3)
  0.4% death (n = 1)
20.6% discontinued (n = 59)
  11.8% adverse events (n = 34)
  3.8% withdrew consent (n = 11)
  2.4% unsatisfactory therapeutic effect (n = 7)
  2.4% protocol deviation (n = 7)
  0.0% death (n = 0)
84.0% completed the study (n = 242)
  19.4% had at least one criterion which led to 
  exclusion from analysis (n = 56)
77.5% completed the study (n = 220)
  60.2% had at least one criterion which led to
  exclusion from analysis (n = 171)
79.4% completed the study (n = 228)
  53.3% had at least one criterion which led to
  exclusion from analysis (n = 153)
Allocation
Enrollment
Follow-up
Analysis
Assessed for eligibility (n = 1,208)
Excluded (n = 349)
Randomized (n = 859)
  Fig. 1.   Flow chart of the study design and patient participation. 170
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1.34 (95% CI, 0.98–1.83) for the 5-cm  2  (9-mg loading dose; 4.6 mg/24 h delivery rate) rivastig-
mine patch and 1.33 (95% CI, 0.98–1.82) for the 10-cm  2   (18-mg loading dose; 9.5 mg/24 h 
delivery rate) patch in the ITT-LOCF population. Similar results were seen in the MITT, ITT-
OC and PP populations (  table 4  ). Following adjustment for body weight and MMSE, ORs 
were 1.36 (95% CI, 1.00–1.86; p = 0.050) for the 5-cm  2   rivastigmine patch and 1.38 (95% CI, 
1.01–1.88; p = 0.042) for the 10-cm  2   rivastigmine patch (  table 4  ). In categorical analyses, im-
provement in the CIBIC plus-J (markedly, moderately or minimally) at week 24 was more 
often observed in patients  receiving the rivastigmine patch. In the ITT-LOCF population, 
57/269 (21.2%) of participants receiving the 5-cm  2   rivastigmine patch and 59/270 (21.9%) of 
participants receiving the 10-cm  2   rivastigmine patch had improved CIBIC plus-J scores
Table 2. B  aseline characteristics and demographics of the safety population
Placebo R ivastigmine  patch Total
5   cm2 (9-mg loading dose; 
4.6 mg/24 h delivery rate)
10 cm2 (18-mg loading dose; 
9.5 mg/24 h delivery rate)
(n = 286) (n = 282) (n = 287) (n = 855)
Mean age, years (8 SD) 74.587.4 74.387.5 75.186.9 74.687.2
Female patients, % 68.2 68.8 67.9 68.3
Mean weight, kg (8 SD) 50.789.8 50.789.0 50.789.5 50.789.4
Mean time since physician first 
diagnosed AD symptom, years (8 SD) 1.781.9 1.681.7 1.781.8 1.781.8
Participants’ living situation, %
Living alone
Living with caregiver/other individual
Assisted living/group home
Nursing home/long-term institution
Other
1.7
96.5
0.7
1.0
0.0
1.4
94.7
2.5
1.1
0.4
2.1
95.8
1.4
0.7
0.0
1.8
95.7
1.5
0.9
0.1
Mean formal education, years (8 SD)a 10.582.8 10.782.8 10.382.7 10.582.8
Mean baseline MMSE (8 SD) 16.682.9 16.882.9 16.583.1 16.683.0
Mean baseline total ADAS-J cog (8 SD)b 25.189.7 25.7810.0 25.2810.0 25.389.9
a B  ased on 285, 280, 285 and 850 patients in the placebo, 5- and 10-cm2 patch and total groups.
b Based on 284, 280, 284 and 848 patients in the placebo, 5- and 10-cm2 patch and total groups.
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  Fig. 2.   LS mean (SEM) changes 
from baseline on the ADAS-J cog 
at 24 weeks (ITT-LOCF popula-
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(  table 4  ). While this was not statistically significant for either patch size versus placebo 
(41/267 of participants; 15.4%) in the ITT-LOCF population, the 10-cm  2   rivastigmine patch 
did reach statistical significance versus placebo in the ITT-OC population (p = 0.034) and 
borderline significance in the MITT population (p = 0.049).
  Secondary  Efficacy  Assessments 
  The three subscales of the CIBIC plus-J are DAD, BEHAVE-AD and MENFIS. Partici-
pants receiving either rivastigmine patch size demonstrated efficacy versus placebo in week-
Table 3. M  ean and LS mean ADAS J-cog scores at baseline and changes from baseline at week 24 in the 
ITT-LOCF, ITT-OC, MITT and PP populations
Placebo Rivastigmine 5 cm2
(9-mg loading dose; 
4.6 mg/24 h delivery rate)
Rivastigmine 10 cm2
(18-mg loading dose; 
9.5 mg/24 h delivery rate)
ITT-LOCF
N 268 269 273
n 265 266 268
Baseline (8SD) 24.889.46 25.289.62 25.089.93
Change at week 24 (8SD) 1.385.07 0.584.96 0.185.04
LS mean vs. placebo (8SE) – –0.880.43 –1.280.43
95% CI – –1.7, 0.0 –2.1, –0.4
p value – 0.063 0.005**
ITT-OC
N 268 269 273
n 235 214 218
Baseline (8SD) 24.689.36 25.189.67 25.089.95
Change at week 24 (8SD) 1.285.01 0.685.11 0.185.15
LS mean vs. placebo (8SE) – –0.6 (0.48) –1.1 (0.47)
95% CI – –1.5, 0.3 –2.1, –0.2
p value – 0.204 0.016*
MITT
N 275 274 279
n 271 271 275
Baseline (8SD) 24.989.58 25.489.77 25.089.87
Change at week 24 (8SD) 1.385.17 0.684.95 0.085.15
LS mean vs. placebo (8SE) – –0.8 (0.43) –1.3 (0.43)
95% CI – –1.6, 0.1 –2.1, –0.4
p value – 0.083 0.004**
PP
N 206 169 169
n 200 163 162
Baseline (8SD) 24.489.27 25.289.87 25.2810.41
Change at week 24 (8SD) 1.284.90 0.785.22 0.185.19
LS mean vs. placebo (8SE) – –0.6 (0.53) –1.2 (0.53)
95% CI – –1.6, 0.4 –2.2, –0.1
p value – 0.263 0.026*
*   p < 0.05; ** p < 0.01. Negative change scores on the ADAS-J cog indicate improvement from baseline. 
N = Overall efficacy population; n = number of participants with an evaluation at week 24. For descrip-
tive mean baseline scores and changes from baseline at week 24, only patients with a valid baseline and 
post-baseline score were included (n). For the ITT-LOCF and MITT populations, last observation was 
carried forward to week 24 if appropriate. p values are derived from ANCOVA using treatment as factor 
and baseline score as covariate. 95% CIs are calculated for the treatment difference between LS means.172
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24 scores on DAD and less deterioration on MENFIS (  table 5  ). Delayed progression of wors-
ening was significant for the 10-cm  2  (18-mg loading dose; 9.5 mg/24 h delivery rate) rivastig-
mine patch on scores of MENFIS (p = 0.016) and DAD (p = 0.024;   table 5  ), but significant 
efficacy was not demonstrated for BEHAVE-AD or MMSE scores.    
Table 4. M  ean CIBIC plus-J scores at week 24 in the ITT-LOCF, ITT-OC, MITT and PP populations
Placebo Rivastigmine 5 cm2
(9-mg loading dose; 
4.6 mg/24 h delivery rate)
Rivastigmine 10 cm2
(18-mg loading dose; 
9.5 mg/24 h delivery rate)
ITT-LOCF
N 268 269 273
n 267 269 270
Mean at week 24 (8SD) 4.480.94 4.280.96 4.280.96
p value – 0.063 0.067
OR (95% CI) – 1.34 (0.98, 1.83) 1.33 (0.98, 1.82)
p valuea – 0.050 0.042*
OR (95% CI)a – 1.36 (1.00, 1.86) 1.38 (1.01, 1.88)
Markedly improved, n (%)  0 (0.0) 0 (0.0) 0 (0.0)
Moderately improved, n (%) 5 (1.9) 12 (4.5) 6 (2.2)
Minimally improved, n (%) 36 (13.5) 45 (16.7) 53 (19.6)
Unchanged, n (%) 111 (41.6) 109 (40.5) 109 (40.4)
Minimally worse, n (%) 84 (31.5) 82 (30.5) 78 (28.9)
Moderately worse, n (%) 29 (10.9) 21 (7.8) 22 (8.1)
Markedly worse, n (%) 2 (0.7) 0 (0.0) 2 (0.7)
ITT-OC
N 268 269 273
n 239 218 223
Mean at week 24 (8SD) 4.480.95 4.280.98 4.280.99
p value – 0.031* 0.054
OR (95% CI) – 1.44 (1.03, 2.01) 1.39 (0.99, 1.94)
OR (95% CI)a – 1.46 (1.04, 2.04) 1.48 (1.06, 2.08)
MITT
N 275 274 279
n 273 274 276
Mean at week 24 (8SD) 4.480.94 4.280.98 4.280.96
p value – 0.151 0.087
OR (95% CI) – 1.25 (0.92, 1.70) 1.30 (0.96, 1.77)
OR (95% CI)a – 1.26 (0.93, 1.71) 1.33 (0.98, 1.81)
PP
N 206 169 169
n 199 165 165
Mean at week 24 (8SD) 4.480.92 4.280.97 4.281.00
p value – 0.065 0.029*
OR (95% CI) – 1.42 (0.98, 2.07) 1.53 (1.05, 2.23)
OR (95% CI)a – 1.45 (1.00, 2.12) 1.62 (1.10, 2.37)
*   p < 0.05. N = Overall efficacy population; n = number of participants with an evaluation at week 24. 
ORs are from week 24 scores for treatment vs. placebo based on a proportional odds regression model;
a score >1 represents an outcome in favor of rivastigmine. There are no baseline scores for the CIBIC
plus-J because this is scored as a judgment of change and at baseline there is no comparison on which to 
base a judgment. For the ITT-LOCF and MITT populations, last observation was carried forward to week 
24 if appropriate. p values are derived from the Wilcoxon test and are based on pairwise comparisons of 
the rivastigmine and placebo treatment groups.
a Adjusted with allocation factors (weight and MMSE).173
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  Safety  and  Tolerability 
  The number and percentage of participants in each treatment group experiencing ad-
verse events (AEs; at least 5% of participants, safety population) are summarized in   table 6  . 
The most common AEs were consistent with the known safety profile of the rivastigmine 
patch, i.e. application site reactions, nausea and vomiting. Other cholinergic effects occurred 
in  ! 5% of patients in any study group, with the incidence of weight loss [placebo 1.4%; 5-cm  2  
(9-mg loading dose; 4.6 mg/24 h delivery rate) rivastigmine patch 2.5%, and 10-cm  2   (18-mg 
loading dose; 9.5 mg/24 h delivery rate) rivastigmine patch 3.5%], diarrhea (2.4, 3.9 and 3.1%, 
respectively) and anorexia (0.7, 1.1 and 2.1%, respectively) slightly higher in rivastigmine 
treatment than placebo groups.
  Serious AEs occurred in 5.0% of the 5-cm  2  rivastigmine patch group, 6.3% in the 10-cm  2  
rivastigmine patch group and 7.0% in the placebo group.     AEs led to early discontinuation in 
13.8% of participants in the 5-cm  2   patch group, 11.8% in the 10-cm  2   patch group and 7.7% 
Table 5. M  ean secondary efficacy scores at baseline and changes from baseline at week 24 (ITT-LOCF 
  participants with valid baseline and post-baseline scores)
Efficacy variable Baseline score
(mean 8 SD)
Changes at 
week 24
(mean 8 SD)
24-week 
difference 
(p-value)
Secondary efficacy variables
MMSE score
Placebo (n = 251)
Rivastigmine 5-cm2 patch (n = 236)
Rivastigmine 10-cm2 patch (n = 246)
16.782.87
16.982.88
16.483.09
–0.382.82
–0.383.05
0.082.87
–
0.758
0.260
CIBIC plus-J DAD score
Placebo (n = 267)
Rivastigmine 5-cm2 patch (n = 269)
Rivastigmine 10-cm2 patch (n = 269)
66.7819.90
64.2820.57
64.2821.92
–4.2812.44
–3.0810.26
–1.9810.66
–
0.270
0.024*
CIBIC plus-J BEHAVE-AD score
Placebo (n = 267)
Rivastigmine 5-cm2 patch (n = 269)
Rivastigmine 10-cm2 patch (n = 270)
4.884.50
4.784.96
5.485.15
–0.183.76
–0.184.17
–0.384.70
–
0.911
0.795
CIBIC plus-J MENFIS score
Placebo (n = 267)
Rivastigmine 5-cm2 patch (n = 269)
Rivastigmine 10-cm2 patch (n = 270)
23.2811.13
24.3811.72
24.6811.36
2.986.18
2.285.86
1.685.82
–
0.192
0.016*
Exploratory efficacy variables
Modified Crichton Scale score
Placebo (n = 268)
Rivastigmine 5-cm2 patch (n = 269)
Rivastigmine 10-cm2 patch (n = 272)
17.388.65
17.388.87
18.289.29
2.987.40
2.287.44
1.687.43
–
0.256
0.040*
*   p < 0.05. Negative change scores on BEHAVE-AD, MENFIS and the Modified Crichton Scale indicate 
improvement. Negative change scores on the MMSE and DAD indicate deterioration. For the CIBIC 
  plus-J, descriptive mean scores and changes from baseline are shown but p values are derived from AN-
COVA using treatment as factor and baseline score as covariate and are based on LS mean comparisons 
for each rivastigmine group [5-cm2 patch (9-mg loading dose; 4.6 mg/24 h delivery rate) and 10-cm2 riv-
astigmine patch (18-mg loading dose; 9.5 mg/24 h delivery rate)] vs. placebo. For the MMSE, p values are 
derived from the Wilcoxon test and are based on pairwise comparison of rivastigmine and placebo treat-
ment groups.174
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in the placebo group; among the most common were application site reactions and skin and 
subcutaneous tissue disorders.
  There were 2 deaths during the study period. One participant in the 5-cm  2  rivastigmine 
patch group died of aspiration pneumonia and 1 participant in the placebo group died of 
subarachnoid hemorrhage. The deaths were not suspected to have a causal relationship with 
the study drug.
    Patch Adhesion and Skin Irritability 
 When evaluating the total number of participants with an evaluation for each patch size, 
491/522 (94.1%) of the 5-cm  2   (9-mg loading dose; 4.6 mg/24 h delivery rate) rivastigmine 
patches and 200/215 (93.0%) of the 10-cm  2   (18-mg loading dose; 9.5 mg/24 h delivery rate) 
rivastigmine patches remained completely or well attached.
  Investigator rating of skin tolerability (most severe rating) based on patch size and treat-
ment (safety population) is summarized in   figure 3  . When evaluating the total number
of evaluations for each patch size, 444/522 (85.1%) of participants who received the 5-cm  2  
rivastigmine patch and 178/214 (83.2%) of participants who received the 10-cm  2  rivastigmine 
patch had no, slight or mild skin irritation. In the 5-cm  2   rivastigmine patch group, the most 
c o mm o n  sev e r e  s kin  irri ta ti o n  was  e ryth e m a  ( 8 / 5 2 2  p arti ci p an ts;  1 .5 % ) .  In  th e  1 0-cm  2  
  rivastigmine patch group, the most common severe skin irritation was pruritus (6/214 of 
participants; 2.8%).
  Exploratory  Assessments 
 The Modified Crichton Scale deteriorated in all treatment groups from baseline to week 
24. However, there was less deterioration in scores on the Modified Crichton Scale and a sig-
nificant treatment difference versus placebo at week 24 in participants treated with the 10-
cm  2   (18-mg loading dose; 9.5 mg/24 h delivery rate) rivastigmine patch (p = 0.040).
  The results of a survey conducted to investigate the usefulness of patch formulation com-
pared with the existing oral formulation demonstrated that 510/842 (61%) of Japanese care-
givers thought that the patch was ‘easy’ or ‘considerably easy’ to use.
  T h e   m e a n   ( 8  SD) trough plasma concentration of rivastigmine at week 24 was deter-
mined to be 2.61 (  8  1.74) ng/ml in the 5-cm  2   (9-mg loading dose; 4.6 mg/24 h delivery rate) 
rivastigmine patch group and 8.10 (  8  7.16) ng/ml in the 10-cm  2   (18-mg loading dose;
Table 6.   Most frequently reported AEs regardless of the study drug relationship (occurring in ≥5% of pa-
tients in the safety population)
Placebo R ivastigmine  patch
5 cm2   (9-mg loading dose;
4.6 mg/24 h delivery rate)
10 cm2 (18-mg loading dose; 
9.5 mg/24 h delivery rate)
(n = 286) (n = 282) (n = 287)
Patients with an AE, n (%) 222 (77.6) 243 (86.2) 248 (86.4)
Application site erythema 55 (19.2) 106 (37.6) 113 (39.4)
Application site pruritis 61 (21.3) 92 (32.6) 100 (34.8)
Application site edema 7 (2.4) 35 (12.4) 31 (10.8)
Application site exfoliation 4 (1.4) 14 (5.0) 11 (3.8)
Dermatitis contact 40 (14.0) 69 (24.5) 68 (23.7)
Nasopharyngitis 32 (11.2) 22 (7.8) 33 (11.5)
Nausea 9 (3.1) 3 (1.1) 20 (7.0)
Vomiting 11 (3.8) 11 (3.9) 23 (8.0)175
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9.5 mg/24 h delivery rate) rivastigmine patch group. The mean ( 8 SD) plasma BuChE inhibi-
tion at week 24 was 21.2% (  8  30.1) in the 5-cm  2   rivastigmine patch group and 43.0% (  8 21.8) 
in the 10-cm  2   rivastigmine patch group.
  Discussion 
 The results of this 24-week, multicenter, randomized, double-blind, placebo-controlled, 
parallel-group, dose-finding study show that the rivastigmine transdermal patch may be ef-
fective at delaying symptomatic decline in Japanese patients with probable AD. Our findings 
support the clinical effectiveness, favorable tolerability and known safety profile of the 
  rivastigmine patch for the treatment of patients with mild-to-moderately severe AD, and 
demonstrate its potential for the treatment of Japanese patients with probable AD.
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    With respect to primary efficacy assessments, the 10-cm  2   (18-mg loading dose;
9.5 mg/24 h delivery rate) rivastigmine patch demonstrated significant benefit on the
ADAS-J cog. The LS mean difference for the 10-cm  2   rivastigmine patch versus placebo was 
–1.2 points (p = 0.005), which was similar to that of the IDEAL study [–1.57; unpubl. data]. 
For the CIBIC plus-J, a trend for benefit with the 10-cm  2   rivastigmine patch just missed 
formal statistical significance in the ITT-LOCF population (p = 0.067). Even though the 
evaluated number of participants was decreased, statistical significance was reached in the 
PP population (p = 0.029). In addition, efficacy of the 10-cm  2  rivastigmine patch versus pla-
cebo at week 24 was more evident in the ITT-OC population (p = 0.054) than the ITT-LOCF 
population. 
  The sensitivity of analyses may be improved by adjusting with MMSE at baseline, which 
is considered to be a factor for CIBIC plus-J evaluation. Indeed, the MMSE score at baseline 
may be inversely proportional to cognitive decline in clinical trials  [17, 18] . Following adjust-
ment for dynamic allocation factors (particularly baseline MMSE score), a statistically sig-
nificant difference was observed in scores on the CIBIC plus-J versus placebo for the 10-cm  2  
rivastigmine patch (p = 0.042, proportional odds model). The dynamic randomization was 
performed successfully and all treatment groups were generally comparable. It is not fully 
understood why statistical significance in scores on the CIBIC plus-J, one of the primary 
endpoints, was not fully met without adjustment. 
    With respect to the secondary efficacy assessments, the 10-cm  2   rivastigmine patch led 
to a significant delay in deterioration or improvement in scores on 2 of 3 CIBIC plus-J sub-
scales (DAD and MENFIS), which could translate into improvements in functioning and 
cognition. No significant difference between rivastigmine and placebo was observed on
the BEHAVE-AD. The overall global impression is judged based on changes in these 3
subscales. Hence, the inclusion of participants with mild-to-moderate AD that did not dis-
play measurable psychiatric symptoms would have impacted the performance of the 
  BEHAVE-AD subscale and may have also influenced the overall sensitivity of the CIBIC 
plus-J evaluation.
    Aside from body weight, the baseline patient characteristics of this study were compa-
rable to IDEAL (mean age: 74.6 vs. 73.6 years; female gender: 68.3 vs. 66.5%; mean weight: 
50.7 vs. 66.6 kg; formal education: 10.5 vs. 9.9 years; mean MMSE score: 16.6 vs. 16.5). There-
fore, it was surprising that unlike IDEAL a statistically significant improvement was not seen 
in terms of change in MMSE score versus placebo at week 24. However, the MMSE is primar-
ily used as a scale to stage AD and is not particularly sensitive for detecting treatment effects 
or tracking natural progression of the disease over a short period of time.
    With respect to safety and tolerability, the 19.7% dropout rate may limit interpretation 
of the results, although this rate is consistent with other clinical trials using the rivastigmine 
patch (e.g. 20.5–21.8%)   [8]   and lower than clinical trials with high-dose oral rivastigmine 
(e.g. 22–35%)  [8, 19–21] . The most common AEs were application site reactions (i.e. erythema 
and pruritus) and contact dermatitis. Other than skin reactions, nausea (7.0%) and vomiting 
(8.0%) were reported in the 10-cm  2  rivastigmine patch group. However, nausea and vomiting 
each lead to discontinuation in only 0.7% of those receiving the 10-cm  2   rivastigmine patch. 
Similarly, the IDEAL study demonstrated the most frequently reported AEs to be nausea and 
vomiting, and most AEs were mild or moderate   [8]  . Serious AEs were rare and correlated 
with the known safety profile of the rivastigmine patch   [8]  .
  A  post-hoc    analysis of the IDEAL trial has shown that the rivastigmine patch is gener-
ally well tolerated, regardless of patient body weight   [22]  . Among patients who received the 
rivastigmine patch, lower body weight, as stratified, was not associated with a higher AE rate. 
In contrast, there was an association between a higher AE rate and low body weight among 
patients receiving rivastigmine capsules. Therefore, transdermal delivery of rivastigmine 177
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may permit low-weight patients, such as Japanese, easier access to target doses than oral ad-
ministration.
    The current study found the rivastigmine patch to demonstrate good skin tolerability 
and adhesion. The proportion of participants who experienced no, slight or mild skin irrita-
tion with the rivastigmine patch ranged from 90.3 (10-cm  2   patch) to 91.6% (5-cm  2   patch). 
Patches were only alternated from the right to the left side of the upper back, and, at some 
dose levels, 2 patches of different size were administered at the same time. Consequently, skin 
irritation may have been lessened by greater rotation of the patch application site. In the 
IDEAL study, the proportion of participants who experienced no, slight or mild skin irrita-
tion with the rivastigmine patch ranged from 90 to 98%   [8]  . The results of our study are 
therefore consistent with earlier studies   [8]  . These results indicate the rivastigmine patch to 
show efficacy and to be well tolerated in Japanese patients with AD.
  Rivastigmine is a dual inhibitor of acetylcholinesterase (AChE) and BuChE. Both AChE 
and BuChE can regulate the activity of acetylcholine in the human brain   [23, 24]  ; BuChE 
may become more important as AD progresses  [25–28] , and BuChE is capable of compensat-
ing for AChE function when AChE is deficient   [29]  . There is a growing consensus among 
many experts that BuChE, as well as AChE, is a clinically relevant treatment target in AD 
  [30–37]  . A well-correlated inhibition of BuChE activity in plasma and in cerebrospinal fluid 
has been demonstrated in AD patients treated with rivastigmine, suggesting relevance of 
measuring plasma BuChE activity  [35] . Our exploratory analyses have demonstrated that the 
degree of BuChE inhibition in plasma increases with rivastigmine dose.
    Rivastigmine is the first and only approved transdermal patch for AD. In addition to a 
better tolerability profile when compared to oral rivastigmine (discussed above), transder-
mal delivery may allow better access to optimal therapeutic doses of cholinesterase inhibi-
tors, encourage treatment compliance and offer convenience and emotional advantages to 
the patient and caregiver   [38–40]  . The rivastigmine patch provides visual reassurance that 
the medication is being taken and empowers the caregiver in the administration of treat-
ment. Indeed, a substudy of the IDEAL trial previously showed that 72% of caregivers pre-
ferred patches to capsules for drug delivery, based on ease of use and ease following the 
schedule   [40]  . In this study, we found that 61% of Japanese caregivers thought the patch was 
‘easy’ or ‘considerably easy’ to use compared with existing oral medications.
    As with any clinical trial, there are some limitations relating to the extrapolation of re-
sults from our study to the general AD population. In particular, a main focus of this study 
is also a limitation in that our study was limited to patients with AD from Japan. Neverthe-
less, the results of our study suggest that the rivastigmine transdermal patch has a favorable 
efficacy and tolerability profile in Japanese patients with probable AD. Coupled with the po-
tential practical and emotional benefits associated with transdermal administration of cho-
linesterase inhibitors, the rivastigmine patch may be considered a viable therapeutic option 
for the first-line treatment of patients with AD in Japan. 
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